Listen to Expert Insights on Late-Breaking Data from ASCO 2023

Oncology experts share their perspectives on key data and implications for practice in NSCLC, rectal, prostate, bladder, breast and gynaecologic cancers, and lymphoma

Dr Mansoor Raza Mirza

Chief Oncologist

Rigshospitalet, Copenhagen University Hospital

Denmark

Dr Paolo Tarantino

Medical Oncology

Dana Farber Cancer Institute

United States (US)

Prof. Alexey V Danilov

Professor, Department of Haematology

City of Hope National Medical Center

United States (US)

Prof. Mark Socinski

Medical Oncologist

AdventHealth Cancer Institute, Orlando, Florida

United States (US)

Prof. Evan Yu

Medical Oncologist

University of Washington and Seattle Cancer Care Alliance

United States (US)

Prof. Thomas Powles

Medical Oncologist

Bart's Cancer Centre

United Kingdom (UK)

Assoc. Prof. Gerald Prager

Medical Oncologist

Medical University of Vienna

Austria

Biography Disclosures

Dr Mansoor Raza Mirza

Chief Oncologist

Rigshospitalet, Copenhagen University Hospital

Denmark

Dr Mirza is Chief Oncologist at the Dept. of Oncology, Rigshospitalet, Copenhagen University Hospital, Denmark and Medical Director of the Nordic Society of Gynaecologic Oncology-Clinical Trial Unit (NSGO-CTU). He is also Vice-Chairman of the Danish Society of Gynaecologic Oncology (DGCG).

He is author and principal investigator of several phase I, II and III studies and is chair/member of Independent Data Monitoring Committee (IDMC) of several international trials. He is a senior author of national guidelines for the management of endometrial cancer, cervical cancer, vulvar cancer and nonepithelial ovarian cancer, as well as NSGO radiotherapy guidelines for cervical and vulvar cancers.

He is an ESMO Faculty Member, Member of the Danish Society of Clinical Oncology (DSKO), the European Society of Gynaecologic Oncology (ESGO), the International Gynaecologic Cancer Society (IGCS), the European Society of Therapeutic Radiology and Oncology (ESTRO), the Gynaecologic Oncology Group (GOG, USA) and the American Society of Clinical Oncology (ASCO).

Dr Mansoor Raza Mirza has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Biocad, GSK, Karyopharm, Merck, Mersana, ImmunoGen, Clovis Oncology, Roche, Zai Lab

Biography Disclosures

Prof. Alexey V Danilov

Professor, Department of Haematology

City of Hope National Medical Center

United States (US)

Alexey V. Danilov, MD, PhD, is a Professor of Medicine at the City of Hope National Medical Center, in Los Angeles, CA. He earned his medical degree and PhD at Yaroslavl State Medical Academy in Russia and completed a fellowship in hematology/oncology at Tufts Medical Center, in Boston, Massachusetts. Dr Danilov runs an independently funded clinical/translational program in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) that bridges the understanding of B-cell biology with early clinical evaluation of novel therapeutics. He spearheads a translational and early-phase therapeutics effort in B-cell malignancies at the Knight Cancer Institute. In the laboratory, he focuses on targeting stromal-mediated pro-survival signaling in lymphoid malignancies. He has characterized promising therapeutic agents with regard to their mechanism of action and resistance, ushering them into early-phase clinical trials in CLL and NHL. He seeks to translate his findings to clinical care by developing protocols that advance current treatment paradigms. His work has received support from the Leukemia & Lymphoma Society, Lymphoma Research Foundation, the National Cancer Institute, and the Southwest Oncology Group, among other funding organizations. He has been published in numerous peer-reviewed journals including Clinical Cancer Research, Cancer Research, Haematologica, Molecular Cancer Therapeutics, Journal of Immunology and others. Among numerous speaking engagements, Dr Danilov has chaired sessions at the American Society of Hematology Annual Meetings, and has given visiting professor lectures in London and New York. He is a member of the American Society of Hematology and the European Hematology Association. Dr Danilov is a Leukemia & Lymphoma Society Scholar in Clinical Research and a Lymphoma Research Foundation Clinical Investigator.

Prof. Alexey V Danilov has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Abbvie, AstraZeneca, Bayer Oncology, BiGene, Bristol Myers Squibb, Genentech, MEI, SecuraBio, Takeda Oncology and TG Theraputics

Biography Disclosures

Prof. Mark Socinski

Medical Oncologist

AdventHealth Cancer Institute, Orlando, Florida

United States (US)

Prof. Mark Socinski is a Medical Oncologist and Executive Medical Director of the AdventHealth Cancer Institute, Orlando, Florida. Specialises in all thoracic malignancies, including small cell and non-small cell lung cancers and mesothelioma. An internationally recognised expert in the development of novel chemotherapy agents and treatment strategies for advanced non-small cell lung cancer and small cell lung cancer. Research has focused on incorporating personalised medicine and molecular biomarkers in the treatment of lung cancer. Formerly Co-Chair of the Thoracic Malignancies Steering Committee for the National Cancer Institute and served on the Respiratory Core Committee of the Cancer and Leukemia Group B (Alliance). Tenured Professor at the University of North Carolina and the University of Pittsburgh.

Prof. Mark Socinski has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, BMS, Eli Lilly, Genentech, GI Therapeutics, Guardant, Janssen, Jazz, Merck, Novartis.

Prof. Evan Yu

Medical Oncologist

University of Washington and Seattle Cancer Care Alliance

United States (US)

Evan Y. Yu, M.D., is a medical oncologist specializing in prostate, bladder, and testicular cancer treatment and research. He graduated Alpha Omega Alpha from the University of Washington School of Medicine. He completed internal medicine residency at the Brigham and Women’s Hospital and oncology fellowship and post-doctoral training at the Dana-Farber Cancer Institute. He returned to Seattle at the end of 2004 to join the faculty at the University of Washington and Fred Hutchinson Cancer Research Center. Dr Yu is a Full Professor of Medicine and Oncology, the Clinical Research Director for GU malignancies, Core Director for the Pacific Northwest Prostate Cancer SPORE and co-PI of the DoD Prostate Cancer Clinical Trials Consortium for his institution. His research focuses on testing the next wave of novel molecular targeted therapies and immunotherapy techniques, with a complementary focus on imaging biomarkers. In addition to an active clinical and research practice, he also is the Medical Director for Clinical Research Services at the Fred Hutchinson Cancer Consortium. Previously, he served as a Hematology/Oncology Fellowship Program Director for a decade at the Fred Hutchinson Cancer Research Center. He has regularly been voted a “Top Doctor” by Castle Connolly, U.S. News and World Report, Seattle magazine, and Seattle Met magazine. He has served for many years on the National Cancer Institute Genitourinary Cancers Steering Committee and is the Co-Chair for the National Cancer Institute Prostate Cancer Task Force. Dr Yu remains active in SWOG, the Cancer Immunotherapy Trials Network and he also serves as a senior editor for Clinical Cancer Research and Uro-Today.

Biography Disclosures

Assoc. Prof. Gerald Prager

Medical Oncologist

Medical University of Vienna

Austria

Dr Gerald Prager is an Associate Professor of Medicine, Board Certified for Internal Medicine Board and Certified for Haematology and Medical Oncology. In 2009, he received his M.D. from the University of Vienna. Currently, Dr Prager is Director of the Colorectal Cancer Unit of the Department of Medical Oncology at the Medical University of Vienna. He is also a member of the ESMO 2014 Scientific Committee. The research interest of his lab focuses on (tumour-) angiogenesis via regulation of endothelial cell survival and migration by cell / extracellular-matrix interaction. Through his clinical training in haemato-oncology, he became a member of the sought-after group of medical researches. He achieved his expertise in international renowned labs at University of California, San Diego, the Norris Cancer Center, Los Angeles and the Department of Vascular Biology, Mississippi University for Women (MUW). His work is honoured by 19 international awards and resulted in publications in international highly renowned journals. Dr Prager’s young research group is embedded in an international cancer research campus associated with Medical University of Vienna (MUV).

Assoc. Prof. Gerald Prager has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, AstraZeneca, Bayer, BMS, Incyte, Merck Serono, MSD, Servier, Takeda

Non-Small-Cell Lung Cancer Update: ADAURA trial

time @ASCO23 | open 2 min | Jun 2023

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

Clinical takeaways:

The ADAURA trial demonstrated statistically and clinically significant overall survival benefit with osimertinib in patients with resected EGFRm stage IB-IIIA NSCLC
Adjuvant osimertinib reduced the risk of death by approximately half compared to placebo in these patients
The effect was consistent irrespective of stage of disease and prior adjuvant chemotherapy
Adjuvant osimertinib should be the standard of care for patients with resected EGFRm stage IB-IIIA NSCLC

Coming soon: Additional Precision Oncology updates from ASCO and WCGIC

Prostate and Bladder Cancer Update: PEACE-1, THOR and Norse trials

time @ASCO23 | open 5 min | Jun 2023

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

Clinical takeaways:

Prostate: PEACE-1 trial

Combining prostate radiotherapy with intensified systemic treatment (ADT plus abiraterone +/- docetaxel) did not improve overall survival in men with de novo mCSPC and low metastatic burden but did improve rPFS

Bladder: THOR and Norse trials

The THOR and Norse studies reinforce the activity of erdafitinib as personalised therapy for metastatic urothelial cancer patients with FGFR mutations
All metastatic urothelial patients should be tested for FGFR3/2 alterations, preferably at first diagnosis

Coming soon: Prof. Thomas Powles shares his views on late-breaking RCC data from ASCO 2023

Breast Cancer Update: NATALEE, SONIA and TROPiCS-02 trials

time @ASCO23 | open 2 min | Jun 2023

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

Clinical takeaways:

NATALEE trial has reached primary end point (iDFS) in interim analysis, supporting the potential role of ribociclib to improve outcomes for patients with stage II or III, HR+/HER2- early breast cancer at high risk of recurrence. Further follow up needed to confirm the benefit
The SONIA trial challenges current CDK4/6 inhibition sequencing strategies for patients with HR+/HER2- advanced breast cancer. Results suggest the use of CDK4/6i in first line treatment does not improve PFS2, OS or QoL but does increase toxicities, costs and treatment exposure when compared to second line
TROPiCS-02 trial results reinforce the role of sacituzumab govitecan (SG) for chemo-refractory patients with HR+/HER2- metastatic breast cancer. The study reports a significant OS improvement when using SG compared to chemotherapy, irrespective of HER2-low status or Trop2 expression

Coming soon: New Oral Endocrine Therapy Options in Breast Cancer - an interactive online event hosted by breast cancer experts. Register here.

Rectal Cancer Update: PRODIGE 23 and PROSPECT trials

time @ASCO23 | open 3 min | Jun 2023

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

Clinical takeaways:

PRODIGE 23 trial

Induction chemotherapy with mFOLFIRINOX prior to preoperative chemoradiotherapy significantly improved overall survival compared with standard of care in patients with locally advanced rectal cancer
7-year data confirms the benefit of neoadjuvant therapy in these patients

PROSPECT trial

After 5 years, neoadjuvant FOLFOX with selective use of 5-FU chemoradiotherapy (5-FU CRT) was non-inferior to 5-FU CRT for disease-free survival in participants with locally advanced rectal cancer
Omitting radiation therapy can reduce short- and long-term side effects that impact QOL, while providing similar outcomes in disease-free survival and overall survival

Gynaecologic Cancer Update: DUO-O, SHAPE and KEYNOTE-826 trials

time @ASCO23 | open 3 min | Jun 2023

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

Clinical takeaways:

DUO-O trial: Immunotherapy demonstrates positive Phase 3 results in advanced ovarian cancer, particularly for HR-deficient patients with high unmet needs, supporting its inclusion in the treatment regimen
SHAPE trial: Practice-changing data demonstrates that in early-stage, low-risk cervical cancer, simple hysterectomy is non-inferior to radical hysterectomy in terms of pelvic recurrence rate at 3 years, supporting its adoption as a preferred treatment option
KEYNOTE-826 trial: Pembrolizumab combined with chemotherapy, with or without bevacizumab, shows significant overall survival (OS) and progression-free survival (PFS) benefits in persistent, recurrent, or metastatic cervical cancer, warranting its use as a new standard of care. No new safety concerns arise with long-term follow-up

Lymphoma Update: SWOG S1826 trial

time @ASCO23 | open 2 min | Jun 2023

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

Clinical takeaways:

Nivolumab with AVD significantly improved progression-free survival compared with brentuximab vedotin with AVD in patients with advanced-stage Hodgkin lymphoma (age ≥ 12 years)
Nivolumab with AVD shows a favourable toxicity profile with lower frequency of neuropathy compared with brentuximab vedotin with AVD
Nivolumab with AVD could become the new standard of care and is a key step toward harmonising the paediatric and adult treatment of advanced-stage classic Hodgkin lymphoma

This update is brought to you by COR2ED

Other programmes of interest

Prof. Dimitrios Tsakiris

Dr Lars Asmis

Podcast

2 min

Cancer and Thrombosis

Sep 2023

Dr Elisa Agostinetto

Prof. Valentina Guarneri

Interactive patient case

15 min

Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Meta...

Sep 2023

Prof. Chee-Kiat Tan

Publication

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Listen to Expert Insights on Late-Breaking Data from ASCO 2023

Listen to Expert Insights on Late-Breaking Data from ASCO 2023

Dr Mansoor Raza Mirza

Dr Paolo Tarantino

Prof. Alexey V Danilov

Prof. Mark Socinski

Prof. Evan Yu

Prof. Thomas Powles

Assoc. Prof. Gerald Prager

Non-Small-Cell Lung Cancer Update: ADAURA trial

Prostate and Bladder Cancer Update: PEACE-1, THOR and Norse trials

Breast Cancer Update: NATALEE, SONIA and TROPiCS-02 trials

Rectal Cancer Update: PRODIGE 23 and PROSPECT trials

Gynaecologic Cancer Update: DUO-O, SHAPE and KEYNOTE-826 trials

Lymphoma Update: SWOG S1826 trial

Other programmes of interest

Other programmes developed by Prof. Alexey V Danilov

Prof. Alexey V Danilov

Other programmes developed by Prof. Evan Yu

Prof. Evan Yu

Other programmes developed by Prof. Thomas Powles

Prof. Thomas Powles

Other programmes developed by Assoc. Prof. Gerald Prager

Assoc. Prof. Gerald Prager